We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A phase II study of cisplatin and continuous infusion of vindesine in metastatic head and neck squamous cell cancer.
- Authors
Tellez-Bernal, Eduardo; Recondo, Gonzalo; Guillot, Thierry; Benhamed, Mohamed; Domenge, Christian; Izzo, Julie; Cvitkovic, Esteban; Armand, Jean Pierre; Tellez-Bernal, E; Recondo, G; Guillot, T; Benhamed, M; Domenge, C; Izzo, J; Cvitkovic, E; Armand, J P
- Abstract
The chemotherapeutic treatment of recurrent and/or metastatic squamous cell carcinoma (SCC) of the head and neck (H & N) has a very dismal prognosis, with survival usually not exceeding 1 year. Reported objective response rates vary between 3% and 70%. This difference appears largely attributable to the heterogeneity of the patient populations included in most published Phase II studies in H & N cancer. They usually include together initially metastatic, recurrent, and post primary treatment metastatic disease patients. These patients respond differently to chemotherapy. Because of this situation, we decided to study a more homogeneous patient population consisting of metastatic patients only. Cisplatin (CDDP) and vindesine (VDS) are active agents in H & N SCC. As VDS has a cycle-specific activity, the therapeutic index may be increased if it is administered in a continuous infusion (CI) schedule. Thirty-three patients with metastatic H & N (69% biopsy proven) were treated with a combination regimen including CDDP (100 mg/m2) day 1 and VDS 0.6 to 1 mg/m2 for 96 hours of CI. Thirty-one patients were evaluable for response: five had a complete response (CR; 16%) and 11 had a partial response (PR; 36%) with an overall rate response of 52% (95% confidence limit: 33% to 70%). Median duration of CR was 6.4 months (3 to 19 months) and 4.4 months for PR (3 to 6 months). A decrease in the leukocytes was the main toxicity encountered with this regimen. This combination regimen containing CDDP and CI VDS was well tolerated and active in H & N SCC. The incorporation of an active vinca-alkaloid in neoadjuvant regimens should be considered.
- Subjects
ALKALOIDS; ANTINEOPLASTIC agents; BACTERIAL diseases; CISPLATIN; DRUG administration; CLINICAL drug trials; HEAD tumors; INTRAVENOUS therapy; NECK tumors; NEUTROPENIA; SQUAMOUS cell carcinoma; SURVIVAL; DISEASE relapse; DISEASE remission; LEUKOCYTE count
- Publication
Cancer (0008543X), 1990, Vol 66, Issue 4, p640
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19900815)66:4<640::AID-CNCR2820660406>3.0.CO;2-D